Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):949-956. doi: 10.1051/medsci/2019191. Epub 2020 Jan 6.

[Toxicities of immune checkpoint inhibitors and their management].

[Article in French; Abstract available in French from the publisher]

Author information

1
Service de rhumatologie, hôpital Pellegrin, Bordeaux, France.
2
Institut Gustave Roussy, Villejuif, France.

Abstract

in English, French

Immunotherapeutic strategies, notably immune checkpoint inhibitors, have become a standard of care for the treatment of advanced cancers, with a growing spectrum of activity. These monoclonal antibodies target the co-inhibitory signals between tumor cells or antigen-presenting cells and T cells, thereby enhancing antitumour T cell activity. However, the occurrence of immune-related adverse events, that can affect all organ-system, represents a major limiting factor to the clinical development of these antibodies. Management of such toxicity requires a close collaboration between oncologists and organ-specialists, by using glucocorticoids and/or other immunosuppressive therapies, with the common objective not alter anti-tumor response.

PMID:
31903899
DOI:
10.1051/medsci/2019191

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center